Guidance, NICE advice and quality standards in development | Guidance

Showing 321 to 330 of 388

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Sonrotoclax for treating relapsed or refractory mantle cell lymphoma after an anti-CD20 treatment and a BTK inhibitor [ID6654]	Technology appraisal guidance	TBC
Sotatercept for treating pulmonary arterial hypertension [ID6163]	Technology appraisal guidance	TBC
Soticlestat for treating seizures associated with Dravet syndrome in people 2 years and over [TSID12091]	Technology appraisal guidance	TBC
Soticlestat for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over [TSID10632]	Technology appraisal guidance	TBC
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (MA review of TA781) [ID6287]	Technology appraisal guidance	TBC
SpaceOAR hydrogel spacer for reducing rectal toxicity during radiotherapy for prostate cancer (Suspended – referred to technology appraisals)	Medical technologies guidance	TBC
Spartalizumab with dabrafenib and trametinib for untreated BRAF V600 mutation-positive unresectable or metastatic melanoma [ID1668]	Technology appraisal guidance	21 April 2021
Spesolimab for preventing generalised pustular psoriasis flares in people 12 years and over [TSID12086]	Technology appraisal guidance	TBC
Subcutaneous spesolimab 1 ml formulation for preventing generalised pustular psoriasis flares in people 12 years and over [ID6216]	Technology appraisal guidance	TBC
Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer [ID4001]	Technology appraisal guidance	TBC